Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-09-02-2001
Volume 25
Issue 9

With the scarcity of CGMP facilities spurring a production crisis, manufacturers need to optimize their processes and formulations for individual hybridoma cell lines and production systems.

Recent Videos
Behind the Headlines, Episode 10
Jens Schmidt, associate director MSAT at Lonza